Actinium Pharmaceuticals, Inc. (ATNM) is a Healthcare stock trading at $1.11 (as of 2026-08-21), with a market capitalization of $34.90M and a trailing P/E of 3.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
Actinium Pharmaceuticals develops and commercializes therapies for bone marrow transplant conditioning and other adoptive cell therapies, including I-131 apamistamab (Iomab-B), and it earns money only if clinical-stage programs advance toward approval and commercialization.
As a clinical-stage biopharmaceutical company, Actinium's profit model is structurally driven by whether its trial-tested cell therapy candidates (led by I-131 apamistamab, Iomab-B) demonstrate clinically meaningful outcomes that enable future commercialization, rather than by current product revenue.
Business quality (Weak): The most relevant signal investors can track here is Iomab-B's durable complete remission performance in the SIERRA trial, alongside how many patients and transplant centers are enrolling.
| Price | $1.11 |
| Market Cap | $34.90M |
| P/E Ratio | 3.0 |
| EV / EBITDA | -0.2 |
| Price / Book | 1.15 |
| Price / Sales | 0.97 |
| FCF Yield | -66.7% |
| Revenue (TTM) | $90000.00 |
| Net Margin | -37652.2% |
| Revenue Growth (YoY) | -97.7% |
| EPS Growth (YoY) | -14.2% |
| FCF Growth (YoY) | -25.4% |
| Altman Z-Score | -11.95 (distress) |
| Stock P/E | 3.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -86.3% |
| vs Industry | -82.4% |
| Top Institutional Holder | VANGUARD GROUP INC ($1.93M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Sandesh C. Seth |
| Employees | 31 |
| Country | US |
| IPO Date | 2012-12-27 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.